Background
The spine is one of the most common sites for tumor metastasis. 1 It is estimated that approximately 30% of all patients with cancer develop spinal metastasis at some point in their cancer course. 2 Spinal metastatic disease can cause significant morbidity in patients, including pain, hypercalcemia, pathologic fractures, spinal instability, and compression of the spinal cord or cauda equina. 3 Management of spinal metastases can be complex and may benefit from multimodal therapeutic strategies to achieve optimal outcomes.
Stereotactic spinal radiosurgery (SSRS) is an emerging technique that has been developed to deliver highly conformal ionizing radiation doses, designed to control gross disease while simultaneously minimizing dose to surrounding critical structures such as the spinal cord. Current data on SSRS suggest favorable local control rates of approximately 90% at 1 year, complete pain response of approximately 50%, and low rates of highgrade toxicity. 4 However, as with all emerging technologies, understanding the potential complications of novel therapies such as SSRS is fundamental to safely implementing this technology throughout the wider oncology community. The focus of this case and review is the risk of vertebral fracture after SSRS.
Case presentation
A 54-year old male patient presented with a progressively worsening cough. His medical history was notable for smoking half a pack of cigarettes daily for 35 years but was otherwise unremarkable. Further evaluation included an 18 F-fluorodeoxyglucose positron emission/computed tomography (FDG-PET/CT) scan that revealed 2 right upper-lung nodules, 2 enlarged mediastinal lymph nodes, a left adrenal gland lesion, and a lesion involving the left posterolateral elements of the T6 vertebrae ( Fig 1A) . Endoscopically guided biopsy of a right upper-lung nodule and the left adrenal mass revealed concordant poorly differentiated adenocarcinoma of primary lung origin.
After multidisciplinary tumor board discussion, systemic therapy was recommended. The patient was treated with 6 cycles every 21 days of gemcitabine (1250 mg/m 2 / d on days 1 and 8), cisplatin (80 mg/m 2 /d on day 1), and bevacizumab (7.5 mg/kg/d on day 1). A reevaluation with FDG-PET/CT scan 4.5 months after the initial diagnosis showed a mixed response with decreased FDG uptake in the right upper-lung nodules and mediastinal lymph nodes, stable FDG uptake in the left adrenal gland, and increased FDG uptake in the left pedicle of T6 (Fig 1B) . There was no evidence of new metastatic disease.
After further multidisciplinary discussion, continuation of systemic therapy was recommended. The patient was reinitiated on 1 additional cycle of gemcitabine, cisplatin, and bevacizumab (7 total cycles) and then switched to pemetrexed (500 mg/m 2 /d on day 1), carboplatin (area under the curve 6 on day 1), and bevacizumab (15 mg/kg/ d on day 1) for 3 cycles (10 cycles total). Bevacizumab was omitted during the 10th total cycle in preparation for stereotactic radiation therapy.
A reevaluation with FDG-PET/CT scan 7.5 months after initial diagnosis showed further response in the right upper-lung nodules, T6 lesion, and left adrenal. There was complete response involving the mediastinal adenopathy per the Response Evaluation Criteria in Solid Tumors, version 1.1, and no evidence of new distant disease (Fig 1C) . The patient had a total spinal instability neoplastic score (SINS) of 5. 5 The SINS component scores included location (score 1), pain (score 1), bone lesion (score 2), radiographic spinal alignment (score 0), vertebral body collapse (score 0), and posterolateral involvement of spinal elements (score 1). At our institution, surgical consultation is recommended before SSRS for patients with SINS 7.
The patient proceeded with stereotactic body radiation therapy to the right upper-lung nodules (50 Gy in 5 fractions) and left adrenal metastasis (50 Gy in 5 fractions) along with SSRS to the T6 vertebral lesion (24 Gy in 1 fraction; Fig 2) . Radiation therapy was completed 8.5 months after initial diagnosis. For the lung nodules, an internal gross tumor volume (GTV) was created, which represented gross disease on all respiratory phases. The left adrenal GTV was identified on the breath hold scan. The planning target volume (PTV) was created by expanding the internal GTV/GTV by 0.5 cm isometrically. For the spine lesion, 2 target volumes were delineated, including a high-dose 24 Gy volume, which included all T1 contrast-enhancing disease on magnetic resonance imaging, and a low-dose 18 Gy volume designed by treating approximately 1 cm of at-risk adjacent osseous elements, consistent with published guidelines. 6 The spinal PTVs were created by expanding each respective target volume by 0.2 cm.
Treatment planning was done using the Eclipse Treatment Planning System (Varian, Palo Alto, CA) with a volumetric multiarc approach. Dose constraints were followed per the report of the American Association of Physicists in Medicine Task Group 101. 7 Critical constraint objectives for the spinal lesion included cord maximum <14 Gy and D1.2cc[Gy] <7 Gy. Treatments were delivered on consecutive days. Image guidance was done with daily cone beam CT using a 3 degree-of-freedom robotic couch for lung and adrenal targets matched to PTV. An integrated ExacTrac system (Brainlab AG, Munich, Germany) was used for the T6 lesion with tolerance set at 1 mm and 0.5 matched to the T6 bony anatomy. After completing radiation therapy, the patient completed 2 additional cycles of pemetrexed and carboplatin (12 total cycles), followed by reevaluation 12 months after the initial diagnosis; FDG-PET/CT scan showed no evidence of disease (Fig 1D) . The patient remained disease-free more than 6 years after the initial diagnosis. However, after >5 years of freedom from disease after SSRS, the patient presented with sharp, stabbing pain at an area of kyphosis at the T6 level, associated with periscapular pain that radiated around to the anterior chest. Imaging revealed a compression fracture at T6 (Fig 3) . Consequently, the patient underwent T5-T7 laminectomy, bilateral T6 nerve root rhizotomy, T5-6 and T6-7 discectomies, and T6 vertebrectomy along with posterior spinal fusion of T3-T9 and anterior spinal fusion of T5-T7. Pathology test results showed fragmented bone with degenerative changes and osteonecrosis with reactive fibrovascular proliferation. No malignancy was identified. The has since recovered from this operation and returned to his active lifestyle with expected spinal mobility limitations.
Ethics approval for this report was obtained by the ethics committee governed by the Mayo Clinic internal review board. Informed consent was obtained from the patient while under our care. Before the writing of this manuscript, patient consent was obtained to use his medical information for the purposes of research and advancing medicinal science, including publication of this report.
Discussion
SSRS has emerged as an excellent treatment option for patients with oligometastatic spinal disease, as outlined in the American College of Radiology appropriateness criteria. 8 The decision to treat with SSRS should be made carefully by clinicians who are properly trained in this technologically advanced technique. Once appropriate selection of patients has occurred, recognition of treatment complications and every effort to mitigate such complications should be reviewed. The present case highlights the complication of vertebral compression fracture post-SSRS. The patient had metastatic adenocarcinoma of the lung and after 10 cycles of chemotherapy was found to have no new evidence of distant metastasis despite 4 oligometastatic sites that demonstrated radiographic disease persistence. These 4 sites were treated with stereotactic radiation therapy, and the patient has had a sustained complete response. However, despite the excellent oncologic outcome, 5 years after SSRS, the patient developed a vertebral compression fracture that required extensive surgical intervention, stabilization, and fixation.
In a review of the current literature, 13 stereotactic radiosurgery studies have been identified that evaluated the risk of vertebral compression fracture.
2,9e20 The rates of fracture are summarized with risk factors identified by univariate and multivariate analysis in Table 1 . Of the 3860 treated vertebral bodies, 474 vertebral compression fractures (12.3%) were identified in this updated review. Risk factors of vertebral compression fracture include preexisting vertebral compression fracture, lytic-type lesion, spinal malalignment or deformity, a high SINS, higher radiation dose per fraction, baseline pain, age, and extent of involvement (Table 1) . Dose per fraction is an important consideration for both tumor control and risk of vertebral fracture. Three of the reviewed studies specifically identified dose as a risk factor on univariate and/or multivariate analysis. 11, 12, 17 Sahgal et al and Cunha et al cautioned physicians of vertebral fracture risk when treating with single-fraction doses of 20 Gy. 11, 12 A more detailed dosimetric analysis was performed by Jawad et al, who showed that an equivalent 2-Gy dose (EQD 2 ) of 41.8 Gy and a prescription target volume dose of 38.4 Gy (EQD 2 ) were predictive of vertebral compression fracture. 17 These are important considerations when designing any high-quality SSRS treatment plan.
Unique features of this case include the delay in time to fracture along with the patient's durable disease control after aggressive metastasis-directed therapy. Previous reviews suggest that the time to fracture most commonly occurs at approximately 3 months post-SSRS.
2,21 The patient's delay in fracture of 5 years post-SSRS may be more related to small vessel changes and demineralization, as opposed to acute structural changes from tumor voids where fracture occurs relatively soon after SSRS. These differences highlight the potential issue of delayed fracture as systemic therapies (eg, targeted and immunemediated therapies) improve and disease control becomes more durable.
Although previous reviews have suggested that time to fracture most commonly occurs approximately 3 months post-SSRS, delayed vertebral fracture risk has been demonstrated in some series. For example, Moussazadeh et al reported a median time to vertebral compression fracture of 25.7 months (range, 11.6-76.0). 22 The authors suggested that their observed longer time to the development of a fracture may be accounted for by carefully screening patients for symptomatic and radiographic mechanical instability before SSRS. Any patient with a symptomatic fracture causing severe instability pain (visual analog score >6) was treated in the Moussazadeh et al series with prophylactic vertebroplasty with or without instrumented percutaneous stabilization. The presented patient did not have a visual analog pain score >6; in fact, he was largely asymptomatic at the time of SSRS. Furthermore, he was deemed to be at low risk for spinal instability using the SINS (SINS total score Z 5). Nevertheless, he developed delayed vertebral fracture, which may suggest the need for effective mitigation strategies for post-SSRS vertebral compression fracture, even in lower-risk patients if followed long enough.
Ongoing studies are evaluating prophylactic cement augmentation (MDACC 2014-0561, ClinicalTrials.gov, number NCT02387905) to mitigate the risk of vertebral compression fracture for the highest-risk patients (eg, preexisting fracture, SINS of 7-12, and SSRS dose of 24 Gy). This study along with others will further inform our decision making to minimize the complication of vertebral fracture post-SSRS in the future. Minimizing late effects will be important as outcomes improve and patients are living longer but complications could arise.
Conclusions
This teaching case highlights the complication of vertebral compression fracture after SSRS. In review of 13 published SSRS studies, the average rate of vertebral compression fracture was 12.3%. This case emphasizes the continued need for effective mitigation strategies for post-SSRS complications such as delayed vertebral compression fracture.
